基于风险分层的脂肪性肝病相关肝细胞癌发病率用于精准医学:一项真实世界纵向全国性研究
该回顾性队列研究利用美国Merative Marketscan研究数据库(2007年1月至2021年12月)分析741,816例脂肪性肝病患者,随访2,410,166人年期间1,740例发生肝细胞癌,总体发病率为0.72/1000人年(95%CI 0.68-0.75)。按性别、年龄、肝硬化、糖尿病分层后发病率呈递增趋势,最高达19.06/1000人年,最低仅0.04/1000人年。
要点
- 脂肪性肝病患者总体肝细胞癌发病率为0.72/1000人年(95%CI 0.68-0.75)。
- 肝硬化患者发病率4.29/1000人年(95%CI 4.06-4.51),显著高于无肝硬化者0.14/1000人年。
- 男性、高龄、肝硬化、糖尿病四因素叠加时发病率最高达19.06/1000人年。
核心结论
- 该全国性研究提供了按多个关键风险因素分层的脂肪性肝病相关肝细胞癌发病率的稳健精细估计。
- 除肝硬化外,未来的监测策略、预防、公共卫生举措和未来研究模型也应考虑性别、年龄和糖尿病的影响。
研究设计与样本
- 回顾性队列研究,数据来自美国Merative Marketscan研究数据库(2007年1月至2021年12月)。
- 纳入741,816例脂肪性肝病成人患者(平均年龄51.5±12.8岁,46%男性,14.7%肝硬化),排除显著饮酒和慢性病毒性肝炎患者。
- 按性别、年龄、肝硬化、糖尿病及四因素组合分层估计肝细胞癌发病率,随访共2,410,166人年。
主要发现
- 随访期间1,740例患者发生肝细胞癌,总体发病率为0.72/1000人年(95%CI 0.68-0.75)。
- 男性发病率0.95/1000人年(95%CI 0.89-1.01)高于女性0.52/1000人年(95%CI 0.48-0.56)(p<0.001)。
- 肝硬化患者发病率4.29/1000人年(95%CI 4.06-4.51)高于无肝硬化者0.14/1000人年(95%CI 0.13-0.16)(p<0.001)。
- 糖尿病患者发病率1.19/1000人年(95%CI 1.12-1.26)高于无糖尿病者0.41/1000人年(95%CI 0.38-0.44)(p<0.001)。
- 合并慢性肾病者发病率2.20/1000人年(95%CI 2.00-2.41)高于无慢性肾病者0.58/1000人年(95%CI 0.55-0.62)(p<0.001);合并心血管疾病者1.89/1000人年(95%CI 1.75-2.03)高于无心血管疾病者0.51/1000人年(95%CI 0.48-0.54)(p<0.001);合并非肝癌其他癌症者3.90/1000人年(95%CI 3.67-4.12)高于无其他癌症者0.29/1000人年(95%CI 0.26-0.31)(p<0.001)。
关键数值与推荐
- 按10岁年龄间隔、男性、肝硬化、糖尿病逐层叠加后,男性和女性发病率分别最高达19.06/1000人年(95%CI 16.10-22.01)和8.44/1000人年(95%CI 6.78-10.10)。
- 非糖尿病、无肝硬化的40岁以下患者无论男女发病率均仅0.04/1000人年。
临床怎么用
- 原文结论指出未来监测策略、预防、公共卫生举措和研究模型除肝硬化外也应考虑性别、年龄和糖尿病的影响。
局限性
- 该方法学的主要局限是索赔数据库研究中固有的国际疾病分类(ICD)编码潜在错分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detailed subgroup incidence rates for steatotic liver disease (SLD)-related hepatocellular carcinoma (HCC) are critical to inform practice and public health interventions but remain sparse. We aimed to fill in this gap. METHODS AND FINDINGS: In a retrospective cohort study of adults with SLD from the United States (US) Merative Marketscan Research Databases (1/2007 to 12/2021), we estimated HCC incidence stratified by sex, age, cirrhosis, diabetes mellitus (DM), and a combination of all these 4 factors. We excluded patients with significant alcohol use and chronic viral hepatitis. We analyzed data from 741,816 patients with SLD (mean age 51.5 ± 12.8 years, 46% male, 14.7% cirrhosis). During a 2,410,166 person-years (PY) follow-up, 1,740 patients developed HCC. The overall HCC incidence yielded 0.72 per 1,000 PY (95% confidence interval [CI, 0.68, 0.75]). The incidence was higher in males (0.95, 95% CI [0.89, 1.01]) compared to females (0.52, 95% CI [0.48, 0.56]) (p < 0.001). For those with cirrhosis, the incidence was significantly higher at 4.29 (95% CI [4.06, 4.51]) compared to those without cirrhosis (0.14, 95% CI [0.13, 0.16]) (p < 0.001). Additionally, the incidence was higher in patients with DM (1.19, 95% CI [1.12, 1.26]) compared to those without DM (0.41, 95% CI [0.38, 0.44]) (p < 0.001). Chronic kidney disease (CKD) was also associated with a higher HCC incidence of 2.20 (95% CI [2.00, 2.41]) compared to those without CKD (0.58, 95% CI [0.55, 0.62]) (p < 0.001). Similarly, individuals with cardiovascular disease (CVD) had a higher HCC incidence of 1.89 (95% CI [1.75, 2.03]) compared to those without CVD (0.51, 95% CI [0.48, 0.54]) (p < 0.001). Finally, the incidence of HCC was significantly higher in patients with non-liver cancer (3.90, 95% CI [3.67, 4.12]) compared to those without other cancers (0.29, 95% CI [0.26, 0.31]) (p < 0.001). On further stratification, HCC incidence incrementally rose by 10-year age intervals, male sex, cirrhosis, and DM, reaching 19.06 (95% CI [16.10, 22.01]) and 8.44 (95% CI [6.78, 10.10]) in males and females, respectively, but only 0.04 for non-diabetic, noncirrhotic aged <40 years patients in both sexes. The main limitation of this methodology is the potential misclassification of the International Classification of Diseases (ICD) codes inherent in claims database studies. CONCLUSIONS: This nationwide study provided robust granular estimates for SLD-related HCC incidence stratified by several key risk factors. In addition to cirrhosis, future surveillance strategies, prevention, public health initiatives, and future research models should also take into account the impact of sex, age, and DM.
引用
- Lai R, Barnett S, Zhang X, et al. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study. PLoS Med. 2024. PMID: 39453960. doi:10.1371/journal.pmed.1004479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。